We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+47.82%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$808M
AUM Growth
+$260M
Cap. Flow
-$29.2M
Cap. Flow %
-3.62%
Top 10 Hldgs %
40.15%
Holding
122
New
39
Increased
28
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$17.4M
2
VERA icon
Vera Therapeutics
VERA
+$16.7M
3
ONC
BeOne Medicines Ltd
ONC
+$13.2M
4
AUTL
Autolus Therapeutics
AUTL
+$11.4M
5
KURA icon
Kura Oncology
KURA
+$10.5M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$41.6M
2
CBAY
Cymabay Therapeutics
CBAY
+$25.8M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$18.9M
4
LIAN
LianBio American Depositary Shares
LIAN
+$16.9M
5
VKTX icon
Viking Therapeutics
VKTX
+$11.1M

Sector Composition

Rank Sector Weight
1 Healthcare 70.51%
2 Miscellaneous 29.3%
3 Financials 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
51
Cullinan Oncology
CGEM
$1.42B
$4.41M 0.55%
258,588
-41,412
-14% -$640K
MLYS icon
52
Mineralys Therapeutics
MLYS
$2.49B
$4.23M 0.52%
+327,959
New +$4.05M
VKTX icon
53
Viking Therapeutics
VKTX
$4.07B
$4.1M 0.51%
50,000
-250,000
-83% -$11.1M
RZLT icon
54
Rezolute
RZLT
$441M
$4.08M 0.51%
+1,600,000
New +$2.28M
MIRM icon
55
Mirum Pharmaceuticals
MIRM
$6.15B
$4.02M 0.5%
160,000
+110,000
+220% +$3.02M
MLTX icon
56
MoonLake Immunotherapeutics
MLTX
$1.28B
$3.77M 0.47%
75,000
+4,012
+6% +$218K
IMTX icon
57
Immatics
IMTX
$1.46B
$3.68M 0.46%
350,000
+150,000
+75% +$1.75M
ITCI
58
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.46M 0.43%
+50,000
New +$3.44M
ARWR icon
59
Arrowhead Research
ARWR
$12.2B
$3.43M 0.42%
+120,000
New +$3.84M
IBRX icon
60
PUT
ImmunityBio
IBRX
$8.56B
$3.17M 0.39%
+589,400
New +$2.67M
NXTC icon
61
NextCure
NXTC
$35.8M
$3.03M 0.38%
+113,253
New +$1.95M
TERN
62
DELISTED
Terns Pharmaceuticals
TERN
$2.95M 0.37%
450,000
+384,000
+582% +$2.51M
PTGX icon
63
Protagonist Therapeutics
PTGX
$9.43B
$2.89M 0.36%
+100,000
New +$2.72M
FULC icon
64
CALL
Fulcrum Therapeutics
FULC
$294M
$2.6M 0.32%
+275,000
New +$2.45M
BBOT
65
BridgeBio Oncology
BBOT
$720M
$2.59M 0.32%
+250,000
New +$2.59M
ESTA icon
66
CALL
Establishment Labs
ESTA
$2.21B
$2.54M 0.32%
50,000
-175,000
-78% -$7.03M
RGNX icon
67
Regenxbio
RGNX
$590M
$2.32M 0.29%
+110,000
New +$1.96M
NAMSW icon
68
NewAmsterdam Pharma Warrant
NAMSW
$63.8M
$2.24M 0.28%
202,599
+65,599
+48% +$597K
ALKS icon
69
Alkermes
ALKS
$7.73B
$2.03M 0.25%
75,000
-281,384
-79% -$7.99M
AKRO
70
CALL
DELISTED
Akero Therapeutics
AKRO
$1.89M 0.23%
+75,000
New +$1.8M
WVE icon
71
Wave Life Sciences
WVE
$958M
$1.77M 0.22%
+286,585
New +$1.44M
BSX icon
72
Boston Scientific
BSX
$69.3B
$1.71M 0.21%
+25,000
New +$1.61M
KZR
73
DELISTED
Kezar Life Sciences
KZR
$1.59M 0.2%
+176,178
New +$1.6M
BBIO icon
74
BridgeBio Pharma
BBIO
$14.6B
$1.55M 0.19%
50,000
-30,000
-38% -$1.02M
ARYD
75
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.5M 0.19%
+133,500
New +$1.49M
1 2
3
4 5

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Affinity Asset Advisors held 122 positions worth $808M, up 48% from $548M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Affinity Asset Advisors withdrew a net $29.2M in Q1 2024, closing 27 positions and reducing 16 holdings. Its most notable exit was Immunogen Inc, an estimated $41.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 86% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Affinity Asset Advisors opened a new position in Vera Therapeutics worth $20.3M.

  • Affinity Asset Advisors's largest Q1 2024 buy was Vera Therapeutics: 470,000 shares worth $20.3M.
  • Affinity Asset Advisors added most to Xenon Pharmaceuticals in Q1 2024, an estimated $17.4M increase.
  • Affinity Asset Advisors's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $18.9M.
  • Affinity Asset Advisors fully exited Immunogen Inc in Q1 2024, selling an estimated $41.6M.
  • Affinity Asset Advisors's ten largest holdings make up 40% of its $808M portfolio in Q1 2024.
  • Affinity Asset Advisors opened 39 new positions and closed 27 in Q1 2024.
  • Affinity Asset Advisors's portfolio value rose 48% quarter-over-quarter to $808M.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.